Analysts Set Establishment Labs Holdings Inc. (NASDAQ:ESTA) Target Price at $100.25

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has been assigned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $100.25.

Several research analysts have recently weighed in on ESTA shares. TD Cowen upped their price target on shares of Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Canaccord Genuity Group set a $105.00 price objective on Establishment Labs in a research note on Thursday, August 6th. JPMorgan Chase & Co. boosted their target price on Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday. Finally, Citigroup raised Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price target on the stock in a report on Thursday, August 13th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Establishment Labs during the second quarter valued at approximately $135,752,000. William Blair Investment Management LLC bought a new position in shares of Establishment Labs in the 2nd quarter worth $61,273,000. Bank of America Corp DE purchased a new stake in shares of Establishment Labs during the 2nd quarter valued at $52,176,000. Rice Hall James & Associates LLC purchased a new stake in shares of Establishment Labs during the 2nd quarter valued at $48,134,000. Finally, Royce & Associates LP raised its position in shares of Establishment Labs by 24.2% during the 4th quarter. Royce & Associates LP now owns 358,541 shares of the company’s stock valued at $26,130,000 after buying an additional 69,766 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $67.76 on Monday. The company has a 50 day moving average of $78.90 and a 200 day moving average of $74.50. The stock has a market cap of $2.02 billion, a P/E ratio of -51.73 and a beta of 1.05. Establishment Labs has a 12 month low of $37.37 and a 12 month high of $97.59. The company has a current ratio of 3.84, a quick ratio of 2.52 and a debt-to-equity ratio of 12.11.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The firm had revenue of $67.54 million during the quarter, compared to analysts’ expectations of $65.79 million. During the same quarter in the prior year, the company earned ($0.57) earnings per share. The business’s revenue for the quarter was up 31.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Establishment Labs will post -1.15 EPS for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a medical technology company focused on developing, manufacturing and commercializing products for breast aesthetics and reconstruction. Founded in 2004 and headquartered in Alajuela, Costa Rica, the company serves plastic surgeons, healthcare providers and patients in markets around the world.

Its portfolio is centered on the Motiva line of breast implants, including implants designed for cosmetic augmentation and reconstructive procedures. Establishment Labs also develops related technologies and products, including tissue expanders and surgical systems, as well as Mia Femtech, a minimally invasive breast-enhancement procedure and platform.

The company operates internationally through direct sales and distribution partnerships.